

Index

- abdominal distension 378–9
- AC (cyclophosphamide, doxorubicin) 156, 158–60, 294
- adjuvant chemotherapy 153–70
  - after surgery/radiotherapy 274–5
  - DCIS 143–4
  - dose intensification, poor risk patients 160–2
  - high-dose 160, 310–24
  - node-negative, receptor-positive 169
  - node-positive, receptor-positive
    - postmenopausal 169
    - premenopausal 168
  - predictors of response
    - node-negative 211
    - node-positive 213
  - toxicity 161–2
- adjuvant radiotherapy 178–203
- advanced disease 283–302
  - endocrine vs. cytotoxic therapy 285–9
  - principles of therapy 284
- alendronate *see* bisphosphonates
- aminoglutethimide 166, 289–91
- amonifide 298
- analgesic ladder 358–9
- anastrozole 289–91
- androgen receptor gene, X chromosome 64
- angiogenesis, and telomerase inhibitors 335–6
- animal models of breast cancer, and tamoxifen 39
- anthracyclines 269
  - adjuvant therapy 158–60
  - advanced disease 294–5
  - cardiotoxicity 162
- antidepressants 370
- antiemetics 372–3
- antigens, immune response to 333–4
- antioestrogens, 163–6; tumour cell elimination 231
- anxiolytics 374
- apoptosis
  - prediction of response to chemotherapy 254–6
  - regulatory oncogenes 250–2
    - Bcl-2 250–1
    - p53 251–2
- aromatase inhibitors 7, 166, 276, 289–90
- ATAC Study 167
- types I and II 289–90
  - see also* aminoglutethimide; exemestane; letrozole
- aspirin 359–60
- AT gene 64–5
- ATAC Study, aromatase inhibitors 167
- ATP-dependent multidrug resistance proteins (MDPs) 248
- axillary surgery
  - evolution of conservative surgery 16–18
  - management of DCIS 144
- bcl-2, apoptosis
  - prediction of response to chemotherapy 255–6
  - regulation 250–1
- benign breast disease, and HRT 86–7
- biopsy, fine-needle aspiration biopsy 119
- bisphosphonates 340–51
  - advanced disease 298–9, 344–51
  - clinical trials 345–51
    - adjuvant 347–51
    - hypercalcaemia 345
    - skeletal complications 345–7
  - inhibition of bone resorption 365–8
- bone hunger syndrome 341
- bone marrow metastases 301
- bone metastases
  - bone pain 343, 347
  - and bone remodelling 341
  - incidence and morbidity 342
  - invasion and pain 364–5
  - management 343, 363–8
    - bisphosphonates 298–9, 344–51
  - micrometastases 26
- brachial plexopathy 369
- brain metastases 301
  - presentation 375–7
- BRCA1/BRCA2
  - expression patterns 63
  - LoH in DCIS 132
  - mutations 61–3
  - Royal Marsden Tamoxifen Prevention trial 44
- BrdUrd labelling 215

387 Index

- breast cancer diagnosis, nonoperative 118
- breast cancer risk *see* risk factors for breast cancer
- breast cancer surgery *see* surgery
- breast cancer survivors
  - 5-year 104
  - indirect evidence of HRT effects 81–2
  - observational studies 87–9, 88
- breast cancer treatment
  - summary 336
  - see also* advanced; surgery; early; familial
- breast density, HRT and mammography 82–3
- breast reconstruction *see* reconstructive surgery
- British Columbia trial 192
- bupirone 374
- c-erbB-2* (HER-2/*neu*)
  - in DCIS 132
  - marker of lack of response to hormonal therapy 227
  - prediction of response to chemotherapy 253–4
    - neoadjuvant 211–12
  - predictor of response to therapy 213–14
  - trastuzumab 299–300
- CA (cyclophosphamide, doxorubicin) 156, 294
- CAF (cyclophosphamide, doxorubicin, 5-FU) 169, 294–5, 319
- Canada
  - CMF study 9
  - cost study 283
- Cancer and Leukemia Group B (CALGB) study 159–60, 311, 321
- Cancer Research Campaign
  - Adjuvant Breast Trial Working Party 164
  - Current Trials Working Party 165
- capecitabine 297
- carboplatin 298
- cardioprotection
  - dexrazoxane 295
  - lipid-lowering effect of simvastatin 77
  - tibolone 77
- cardiovascular disease risk
  - cardiotoxicity
    - anthracyclines 162, 294
    - mitoxantrone 294
  - reduction measures 77
  - tamoxifen 47–8
- cathepsin D 12
- cell kinetic parameters 209–16
  - dissemination of tumour cells 11–12
  - DNA flow cytometry 210–11
  - history, theoretical considerations 10–12
  - kinetic parameters 209–16
  - predictors of response to therapy 211–16
  - tumour markers 210–11, 227–8, 275–6
- CHART trial, radiotherapy 215–16
- chemoendocrine therapy (5-FU, L-phenylalanine, tamoxifen) 167
  - concurrent vs. sequential 169
- chemoprevention of breast cancer 37–55
  - clinical trials 37–8
  - considered as primary strategy 38–9
  - evolving
    - fenretinide 54–5
    - nutriceuticals 53–4
    - raloxifene 52–3
  - SERMs 52–5
  - see also* tamoxifen
- chemoresistance *see* chemotherapy resistance
- chemotherapy
  - advanced disease 283–302
    - anthracyclines 294–5
    - bisphosphonates 298–9, 340–52
    - dose intensification 298
    - duration of treatment 293
    - fluoropyrimidines 297–8
    - inoperable/operable tumours 265–8
    - single vs. combination 294
    - specific problems 300–2
    - taxanes 295–6
    - trastuzumab 299–300
    - vinorelbine 297
    - with/without prior adjuvant therapy 293
  - combined with/followed by RT 10
  - dose and route 156
  - dose-response effect 311–12
  - drug types 247
  - high-dose 310–24
  - metastatic disease 283–302
  - multimodality concept 265–6
  - predictors of response 209–58
    - clinical studies 253–8
    - HER-2/*neu* 253–4
  - primary medical therapy 264–78
    - adjuvant, after surgery/radiotherapy 274–5
    - advanced inoperable tumours 265–6
    - advanced operable tumours 266–8
    - duration 270
    - endocrine (tamoxifen) 275
    - historical aspects 264–5
    - local recurrence rates 272–3
      - following breast conservation 187–8
    - predictors of response 211–12
    - prognostic factors 275–6
    - radiotherapy timing 272
    - relapse and overall survival 273
    - small tumours 268
    - surgery 270–1
  - and RT
    - timing 272
  - see also* chemoprevention; chemotherapy resistance; high-dose
- chemotherapy regimens 156, 268–70
  - activity, relative 290
  - AC (cyclophosphamide, doxorubicin) 156, 158–60, 294
  - CA (cyclophosphamide, doxorubicin) 156, 294
  - CAF (cyclophosphamide, doxorubicin, 5-FU) 169, 294, 319
    - and dexrazoxane 295

388 Index

- chemotherapy regimens (*cont.*)
  - CMF (cyclophosphamide, methotrexate, 5-FU) 9, 154–6, 158–62, 168, 191–3, 214, 292–3, 199, 311, 319
  - CTCb (cyclophosphamide, BCNU and thiotepa) 321
  - CVAP (cyclophosphamide, doxorubicin, vincristine, prednisolone) 269
  - cyclophosphamide, BCNU and cisplatin 316
  - dose and route 156
  - ECF (5-fluorouracil, epirubicin, cisplatin) 268
  - FAC (cyclophosphamide, doxorubicin, 5-FU) 156
  - FEC (5-fluorouracil, epirubicin, cyclophosphamide) 159, 294, 321
  - 5-FU, L-phenylalanine, tamoxifen 167
  - MOPP (mustine, vincristine, procarbazine, prednisolone) 315
- chemotherapy resistance
  - bcl-2 250–1
  - laboratory studies 247–53
    - distal response mechanisms 250–2
    - drug-specific targets 249–50
    - extrachromosomal DNA and drug resistance 252–3
    - proximal mechanisms 247–9
  - modulation 257–8
  - p53 251–2, 256
- chest wall recurrence 188–9
- chlorpromazine 374, 382
- clinical trials, unpublished 323
- clodronate 347–51
- clonal selection, endocrine-responsive tumours, ER status 231–2
- clonidine 75
- CMF (cyclophosphamide, methotrexate, 5-FU) 154–6, 158–62, 191–3, 292–3, 311, 319
  - Bonnadonna study 199
  - Canadian study, with/without RT 9
  - Danish study, with/without RT 9
  - Milan adjuvant trial 154–6, 158–62, 292–3, 311, 314–15
  - NEAT study 199
  - p53-positive/negative tumours 214, 251–2, 256
  - and prednisolone 168
  - SECRAB study 199
- coanalgesics 360
- Coley's toxins 331
- Collaborative Group on Hormonal Factors in Breast Cancer 83, 84, 89
- colony-stimulating factors (CSFs) 312–13
- confusion 376–7
- conservative surgery *see* surgery
- cosmesis, and optimal local control in breast conservation 183, 201
- Cowden's syndrome 65
- Cox hazards analysis, recurrence/death 194
- COX inhibitors 361
- CTCb (cyclophosphamide, BCNU and thiotepa) 321
- CVAP (cyclophosphamide, doxorubicin, vincristine, prednisolone) 269
- cyclophosphamide, BCNU and cisplatin 316
- cytochrome p-450 inhibitors, oestrogen suppression 289
- Danish Breast Cancer Cooperative Group 9, 191–2, 194
- depression 372
- dextrazoxane, with doxorubicin 295
- dextran-coated charcoal (DCC) adsorption steroid binding assay 222–3
- digital technology, screening 118–19
- DNA, extrachromosomal 252
- DNA flow cytometry 210–11
- docetaxel 269
  - see also* taxanes
- dose intensification
  - advanced disease 298
  - poor risk patients 160–2
- double minutes (extrachromosomal DNA) 252
- doxorubicin
  - with dextrazoxane 295
  - see also* anthracyclines
- ductal carcinoma in situ (DCIS) 126–45
  - classification 129–30
  - diagnosis 133–5
    - frozen sections 135
    - stereotactic core biopsy 134
  - epidemiology 127
  - follow-up and future studies 144–5
  - management 135–44
    - adjuvant medical therapy 143–4
    - axillary surgery 144
    - breast-conserving surgery 138–42
    - CLE alone vs. with radio/chemotherapy 138–40
    - re-excision after 142
    - results 138
    - historical aspects 135–8
    - radiotherapy 142–3
  - molecular biology 132–3
  - natural history 130–2
  - pathology 129
  - risk factors 128
- Dutch National study 321, 322
- dyspnoea 373–4
- early breast cancer
  - high risk disease 320–2
  - need for systemic therapy 26–7
  - randomized trials with autograft support 320–2
  - single-arm trials with autograft support 318
- Early Breast Cancer Trialists' Collaborative Group (EBCTCG) 81, 90, 274
  - duration of tamoxifen 165–6
  - overview (meta-analysis) 157, 159, 163–5, 189–91
  - side-effects of tamoxifen 166
  - steroid receptors 234–6
  - see also* tamoxifen

389 Index

- Eastern Cooperative Oncology Group (ECOG) 166, 168
- ECF (5-fluorouracil, epirubicin, cisplatin) 268
- EGF *see* epidermal growth factor
- elsamitucin 298
- endocrine therapy
  - combination 292
  - vs. cytotoxic therapy in advanced disease 285–9
- ER positivity 285–6
- factors determining response 286
- mechanisms of resistance 228–34
  - acquisition of steroidogenic metabolic pathways 232
  - alteration of secreted proteins 234
  - clonal selection 231–2
  - effect of oncogenes on cell cycle control 234
  - messenger system interactions 234
  - oestrogen receptor mechanisms 228–31
  - production of mitogens 233
  - tumour cell elimination of antioestrogens 231
- primary breast cancer, predictors of response 211
- primary (tamoxifen) 275
- sequential, flow chart 287
- steroid receptors, clinical trials 234–6
  - see also* tamoxifen
- endometrial cancer, tamoxifen studies 46–7, 166–7
- epidemiology, symptomatic vs. screen-detected disease 127–8
- epidermal growth factor receptor
  - marker of lack of response to hormonal therapy 227
  - protein product of *c-erbB-2* 227
- epirubicin *see* anthracyclines
- evening primrose oil 75
- exemestane 167, 289–91
- extensive intraduct component (EIC) 181–2, 186
- FAC (cyclophosphamide, doxorubicin, 5-FU) 156
- familial breast cancer 61–9
  - BRCA1/BRCA2* mutations 61–3
  - HRT risk 84–6
  - other genes 63–4
  - referral, assessment and clinical management 64–9
  - screening 119–20
- faslodex 167
- fatigue 371–2
- FEC (5-fluorouracil, epirubicin, cyclophosphamide) 159, 294
- fenretinide, chemoprevention 54–5, 69
- fine-needle aspiration biopsy 119
- fluoropyrimidines 249
  - advanced disease 297–8
- 5-fluorouracil (5-FU)
  - advanced disease 297–8
  - resistance to 249
    - see also* chemotherapy regimens
- formestane 291
- Forrest Committee, breast cancer screening, recommendations 112
- fractures, pathological 368
- France, PEGASE group 319, 322, 323
- gene therapy 257–8, 337
- glutathione peroxidase (GSHPx) 248
- glutathione S-transferase (GST) 248
- P-glycoprotein, overexpression of 170kDa protein 247
- glycocyrrolate 382
- Gompertzian kinetics 310–11
- gonadomimetics, tibolone 76
- haemopoietic support, high-dose chemotherapy 312–13
- haloperidol 382
- headache 371
- heat shock protein-27 226
- HER-2 receptor protein, Herceptin 236, 334
- HER-2/*neu* *see* *c-erbB-2*
- Herceptin *see* trastuzumab
- high-dose chemotherapy
  - adjuvant chemotherapy 160
  - randomized trials
    - with autograft support 318–22
    - critical analysis 322
    - unpublished 323
  - research priorities 323–4
- strategies 313–16
  - late intensification 313–14, 317
  - multicycle 315–16
  - primary 313
  - sequential 314–15
  - single-arm trials with autograft support 316–18
    - see also* chemotherapy; chemotherapy regimens
- historical aspects
  - chronology of learning 2–6
  - Coley's toxins 331
  - radiotherapy 7–10
  - surgery 1–7
    - evolution of conservative surgery 13–26
    - management of DCIS 135–42
    - theory of spread 10–12
- HMGCoA reductase inhibitors, simvastatin 77
- hormone replacement therapy (HRT) 45, 72–92
  - alternatives 75–8
    - bisphosphonates 76
    - low-dose progestin 76
    - SERMs 77–8
    - short-term HRT 76
  - antagonism between tamoxifen and HRT 90–1
  - benign breast disease 86–7
  - breast cancer risk
    - and cessation of HRT 83
    - high-risk families 84–6
    - meta-analyses 80

390 Index

- hormone replacement therapy (HRT) (*cont.*)
  - mortality and years of use 85
  - breast cancer survivors 74, 77
  - combined therapy 87–9
  - feasibility of randomized trial 91–2
  - HRT risk 81–2
  - observational studies 87–9, 88
  - breast density and mammography 82–3
  - effect on tumour biology 83–4
  - high-risk families 84–6
- hyoscine 382
- hypercalcaemia, clinical trials, bisphosphonates 345
- hyperparathyroidism, and bone remodelling 341
- ibandronate *see* bisphosphonates
- immunology 329–37
  - current clinical studies 334–5
  - evidence of immune response to breast cancer 333–4
  - future approaches 335–7
  - potential for therapy 331–3
  - tumours and 329
- implant
  - and RT, dose distribution 200–1
  - see also* reconstructive surgery
- inflammation, and cancer 330
- interleukins, IL-2, action 333–4
- International Breast Cancer Prevention Study (IBIS) trial 37
- International (Ludwig) Breast Cancer Study Group 168
- Italian GOIRC group 311
- Italian Tamoxifen Prevention Study 41, 42–3
- late intensification model 313–14, 317
- latissimus dorsi (LD) myocutaneous flap 26, 200
- letrozole 167, 289–91
- leucovorin, modulation of chemoresistance 257–8
- LHRH agonists 7
- LHRH analogues 163
- Li–Fraumeni syndrome 63–4
- limb weakness 375–6
- liver metastases 300, 369
  - liver pain 369
- lynestrenol, 19-nortestosterone derivative 89
- magnetic resonance imaging, breast cancer screening 121
- mammography
  - HRT and breast density 82–3
  - see also* screening mammography
- margin status, and local recurrence risk 183–5
- markers (lack of response to endocrine therapy) 210–11, 227–8
  - prolactin 228
  - prostate-specific antigen (PSA) 228
  - transforming growth factor alpha 228
  - urokinase 227–8
- mastectomy
  - avoiding 264–5, 266, 267
  - bilateral prophylactic 38, 68
  - criteria 271
  - post-mastectomy radiotherapy 188–96
  - see also* surgery
- MD Anderson trial 321
- MDR1* gene 247
- megestrol acetate 289–92
  - see also* progestins
- melphalan 298
- menopause, acute, medium/long-term consequences 72–3, 73
- messenger system interactions, endocrine-responsive tumours 233
- metastatic disease
  - chemotherapy 283–302
  - randomized trials with autograft support 318–22
  - single-arm trials with autograft support 316–18
  - sites 300–1
  - therapy, *see* advanced disease
  - see also* bone; brain; liver
- microtubules
  - function, targeting drugs 247
  - taxane cytotoxicity 249
- Milan adjuvant trial (CMF) 154–6, 158–62, 292–3, 311
  - high-dose sequential 314–15
  - poor risk patients, dose intensification 160–2
- minutes, double (extrachromosomal DNA) 252
- mismatch repair genes, *MSH2* and *MLH1* 63
- misoprostol 361
- mitogens, endocrine-responsive tumours 233
- mitoxantrone 320
- MLH1*, Muir–Torre syndrome 63
- molecular biology
  - interphase cytogenetics in DCIS 132
  - oncogenes and steroid receptors 132–3
- monoclonal antibodies, Herceptin *see* trastuzumab
- MOPP (mustine, vincristine, procarbazine, prednisolone) 315
- mouse mammary tumour virus (MMTV), immune response 333
- MSH2* 63
- Muir–Torre syndrome 63
- multidrug resistance (MDR) phenotype 247–9
  - see also* chemotherapy resistance
- Multiple Outcomes of Raloxifene Evaluation (MORE) 37, 78
- National Surgical Adjuvant Breast and Bowel Project (NSABP)
  - B-06 study 179, 180–2
  - B-13 study 187
  - B-14 study, stage I ER-positive cancers 51, 166
  - B-18 study 268–9, 276
  - B-20 study 169
  - B-27 study 269, 275
  - chemoendocrine therapy 167
  - P-1 Breast Cancer Prevention Trial 37, 41, 42

391 Index

- nausea 372–3
- NEAT study 199
- neoadjuvant chemotherapy
  - predictors of response 211–12
  - see also* chemotherapy
- neuropathic pain 369–71
- nm23 12
- NMDA receptor antagonists 370
- node-negative breast cancer
  - predictors of response to therapy 211–12
  - receptor-positive 169
- node-positive breast cancer
  - pre- and postmenopausal 168–9
  - predictors of response to therapy 213
- Nolvadex Adjuvant Trial Organization (NATO) 164
- 19-nortestosterone 89
- Norton–Simon model, growth kinetics of tumours 316
- Nottingham prognostic index (NPI) 27
- NSABP *see* National Surgical Adjuvant Breast and Bowel Project
- NSAIDs **361**
- nuclear retinoid receptors 54
- nutriceuticals 53–4
- ocular effects, tamoxifen studies 47
- oestradiol (serum)
  - conversion to oestrone sulphate 87
  - as indicator of breast cancer recurrence risk 78–81
  - standard HRT dosages 84
  - tamoxifen effects 81
- oestrogen
  - exogenous, and breast cancer survival 81–2
  - OCP 82
  - and ovarian ablation 162–3
  - unopposed replacement in advanced disease 81–2
  - see also* hormone replacement therapy
  - see also* oestrogen-regulated proteins
- oestrogen deficiency 72–5
  - breast cancer survivors 74, 77
  - in women with breast cancer 74–5
  - HRT trials 91–2
- oestrogen receptor (ER) 220–5
  - and adjuvant therapy 162–9, 274
  - ER-ICA 223
  - ER-positive tumours 83, 162–9, 274
    - response to therapy 285–6
  - expression, contralateral breast tumours 235
  - measurement 222–3
    - clinical trials 235–6
  - mechanisms of resistance 228–31
    - absence of ER 229–30
    - exon variants and deletions 230
    - mutations of hormone binding domain 231
  - modulators *see* SERMs
  - and p53 133
  - as predictor of hormone response 223–5
  - status 235
  - structure/function 221–2
- oestrogen-regulated proteins
  - predictors of response to endocrine therapy 225–6
    - heat shock protein-27 226
    - oestrogen-inducible protein (pS2) 225–6
    - progesterone receptor 225
- oncogene receptor, Herceptin 334
- oncogenes
  - effect on cell cycle control 234
  - and steroid receptors, DCIS 132–3
- oophorectomy
  - historical aspects 73
  - ovarian ablation 162–3
  - prophylaxis of ovarian cancer 68, 86
- opioids 361–3
  - alternate 363, **368**
  - formulation and dosage **362**
  - headache 371
  - side-effects 364
  - unfounded fears **365**
- oral contraceptive pill (OCP), oestrogens 82
- osteoporosis, post-menopausal
  - costs 72
  - tamoxifen vs. raloxifene 53
  - tibolone 76
- ovarian ablation 162–3
- ovarian cancer
  - prophylaxis (oophorectomy) 68
  - screening 67
- ovarian suppression, vs. tamoxifen 288
- p53 gene 63
  - tumour status, predictor of response to therapy 213–15
- p53 protein product
  - apoptosis, regulation 251–2
  - in DCIS 133
- p185 receptor tyrosine kinase 335
- P-glycoprotein, overexpression of 170kDa protein 247
- paclitaxel *see* taxanes
- pain
  - incident 368
  - liver 369
  - neuropathic 369–71
- pain palliation 357–71
  - WHO analgesic ladder **358–9**
- palliative care 295–6, 357–82
  - terminal care 379–82
- pamidronate 347–51
- paracentesis 379
- paracetamol 359–60
- paraplegia 375–6
- parathyroid hormone related peptide (PTHrP) 341
- PEGASE group, France 319, 322, **323**
- permeation theory of spread 10–12
- phyto-oestrogens 53–4, 75–6
- plasminogen activator 12
- plasminogen activator inhibitor-1 (PAI-1), regulation of urokinase 227

392 Index

- pleural effusions 301
- Postmenopausal Estrogen/Progestin Intervention (PEPI) trial 82–3
- prednisolone 162–3, 168
- pregnancy, breast cancer prognosis 81–2
- prevention *see* chemoprevention
- primary medical therapy *see* chemotherapy
- progesterone 89
- progesterone receptor (PgR) 84, 225
  - PgR-positive tumours, response to therapy 285–6
- progestins 291–2
  - classification 89
  - in combination with tamoxifen 292
  - in combined HRT, continuous vs. sequential 87
- prognosis, Nottingham prognostic index (NPI) 27
- prolactin, marker of lack of response to endocrine therapy 228
- prophylaxis
  - mastectomy 38, 68
  - post-mastectomy radiotherapy 188–96
  - oophorectomy 68
  - ovarian ablation 162–3
  - ovarian cancer 68, 86
- prostate-specific antigen (PSA), marker of lack of response to endocrine therapy 228
- proteins
  - 42kDa secreted protein, resistance to endocrine therapy 234
  - alteration, secreted, in endocrine therapy 234
  - ATP-dependent multidrug resistance proteins (MDPs) 248
  - c-erbB-2* product 227
  - P-glycoprotein, overexpression 247
  - heat shock protein-27 226
  - HER-2 receptor protein 227, 236, 334
  - oestrogen-inducible (pS2) 225–6
  - oestrogen-regulated 225–6
  - p53 protein product 133, 251–2
  - pS2, oestrogen-inducible protein 225–6
- radiotherapy 178–203
  - dose escalation 185–7
  - and local recurrence risk 182–3
  - 5-year crude rates, EIC and margin status 186
  - margin status 183–5
  - optimizing 196
  - current issues 202
  - sequential vs. synchronous 198–9
  - START study 196–8
  - with surgery
    - breast conservation 178–80, 183
    - breast reconstruction 25, 199–202
    - cosmesis, and optimal local control 183, 201
  - vs. mastectomy, recurrence rates 179
  - post-mastectomy 188–96, 195
  - vs. surgery alone 190
  - TRAM flap 201–2
  - CHART trial 215–16
  - ductal carcinoma in situ (DCIS) 142–3
  - historical aspects 7–10
  - with vs. followed by chemotherapy 10
  - implant, and dose distribution 200–1
  - timing after primary chemotherapy 272
- raloxifene
  - studies 52–3
  - MORE study 37, 78
  - vs. tamoxifen
    - post-menopausal osteoporosis 53
    - US trial 78
- reconstructive surgery 25–6
  - breast-conserving 25–6
  - historical aspects 25–6
  - post-mastectomy with adjuvant RT 199–202
  - dose distribution 201
  - implant reconstruction 200–1
  - TRAM flaps 26, 201–2
- recurrence risk
  - breast-conserving surgery 138, 180–1, 187–8
  - Cox hazards analysis 194
  - and margin status 138–42, 183–5
  - oestradiol (serum), as indicator of recurrence 78–81
  - primary chemotherapy 272–3
  - rates, mastectomy vs. radiotherapy 179
  - see also* risk factors for breast cancer
- retinoic acid receptor (RAR) 54
- RING-1* gene 62, 63
- risk factors for breast cancer 104, 128
  - breast density 82–3
  - Cox hazards analysis, recurrence/death 194
  - high-risk families 61–2, 84–6
  - and HRT
    - breast cancer risk meta-analyses 80
    - high-risk families 84–6
    - mortality and years of use 85
  - moderate-risk families 66
  - multivariate analysis 211
  - and 19–nortestosterone derivatives 89
  - predictive testing 67
  - recurrence following breast-conserving surgery 180–1
  - relative survival, 5-year 104
  - see also* recurrence risk
- Royal Marsden Tamoxifen Prevention trial 39–40, 41, 44
- S-phase fraction (SPF) 210
  - DNA flow cytometry 210, 211
  - prediction of response to neoadjuvant chemotherapy 213
- St Gallen Consensus Panel 158, 165, 168–9
- Scandinavian study 320–1, 322
- screening mammography 103–22
  - adverse effects 116–17
  - benefits 115–16
  - evaluation 107–8
  - evidence for (various ages) 109–11
  - best practice 118
  - costs 106
  - family history screening 119–20

393 Index

- Forrest Committee recommendations 112
- future developments 117–21
- general principles 104–7, 105
- National Screening Programme 67, 103–22
- organizational aspects 111–15
- ovarian cancer 67
- process 113
- purpose 103–4
- quality assurance targets 114
- randomized controlled trials 108–9
- sensitivity/specificity 112–13
- SECRAB study 199
- sedation 381–2
- selenium-dependent glutathione peroxidases (GSHPx) 248
- sentinel node biopsy, axillary surgery 18–24
- SERMs 286–7
  - alternatives to HRT 77–8
  - chemoprevention of breast cancer 52–5
    - see also* raloxifene; tamoxifen; toremifene
- serotonin-uptake inhibitors 75
- serous effusions 301
- simvastatin, cardioprotective lipid-lowering effect 77
- skin metastases 377–8
- soy phyto-oestrogens 53–4, 75–6
- spinal cord compression 375
- START study 196–8
- steroid receptors 220–5, 234–6
  - clinical trials 234–6
  - DCIS 132–3
  - expression, scoring system 224
    - see also specific named receptors*
- steroidogenic metabolic pathways 232
- STh-KLH (Theratope) 334
- Studies of Tamoxifen and Raloxifene (STAR) 37
- suicide gene therapy 335
- surgery
  - conservative surgery 13–26
    - axilla 16–18
    - breast 13–15
    - ductal carcinoma in situ (DCIS) 138–42
    - evolution of conservative surgery 13–26
    - local recurrence, and systemic therapy 187–8
    - optimal local control and cosmesis 183
    - and radiotherapy 179
    - re-excision after 142, 188
    - risk factors for recurrence 180–1
    - sentinel node biopsy 18–24
  - historical aspects 1–7
  - margin status and local recurrence risk 140–2, 183–5
  - operable, randomized controlled trials 277
  - reconstructive surgery 25–6, 199–202
  - with RT
    - breast conservation 178–80
    - dose escalation 185–7
    - vs. mastectomy, recurrence rates 179
    - post-mastectomy 188–96, 195
    - reconstructive surgery 199–202
    - vs. surgery alone 190
  - TRAM flap 26, 201–2
  - timing 24–5
    - see also* mastectomy; reconstructive surgery
- systemic therapy *see* adjuvant systemic therapy; chemotherapy
- tamoxifen 286–7
  - adjuvant 163–5
  - adverse effects 45–8, 166
    - bone density and fractures 48
    - cardiovascular disease 47–8
    - endometrial cancer 46–7, 166–7
    - genotoxicity 50
    - menopausal symptoms and anxiety 45–6
    - ocular effects 47
    - vascular events 46
  - antagonism between tamoxifen and HRT 90–1
  - chemoprevention trials 39–55
    - adverse effects 45–8
    - dose ranges 50–1
    - overview 43–5
    - risk–benefit calculation 49–52
      - see also* EBCTCG
  - duration 165–6
  - elimination by tumour cells 231
  - ER-negative tumours 236
  - ethnic groups 49
  - Italian Tamoxifen Prevention Study 41, 42–3
  - node-negative, receptor-positive breast cancer 169
  - and oestradiol (serum) 81
  - primary medical therapy 275
  - vs. raloxifene
    - post-menopausal osteoporosis 53
    - US trial 78
  - Royal Marsden Tamoxifen Prevention trial 39–40, 41, 44
  - St Gallen Consensus Panel 158, 165, 168–9
  - Studies of Tamoxifen and Raloxifene (STAR) 37
    - see also* chemoprevention of breast cancer; raloxifene; toremifene; Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)
- taxanes 269, 295–6
  - action 295
  - adjuvant 160
  - advanced disease 294–5
  - cytotoxicity 249
  - dosage 296
  - side effects 295
- terminal care 357–82
  - drugs 380
  - later stages 379–82
- terminal restlessness 381–2
- TGF *see* transforming growth factor
- theratope 334
- tibolone 76–7
  - cardioprotective effects 77
  - vs. HRT 76
- topoisomerase II, isoforms, function 249

394 Index

- toremifene, study 52, 167
- transforming growth factors
  - TGF-alpha
    - autocrine stimulus to breast cancer cells 233
    - marker of lack of response to endocrine therapy 228
  - TGF-beta 163–4
  - and production of mitogens 233
- transverse rectus abdominis myocutaneous (TRAM) flap 26, 201–2
- trastuzumab 236, 334
  - advanced disease 299–300
  - targeted therapy 257–8
- trauma, to tumour, cell shedding and metastasis 11–12
- trichilemmomas 65
- trimetrexate 298
- tumours
  - cells, *see also* cell proliferation
  - elimination of antioestrogens 231
  - extensive intraduct component (EIC) 181–2
  - growth kinetics
    - in high-dose chemotherapy strategies 312–16
    - Norton–Simon model 316
  - immune response to 332–4
  - immune system 329–31
  - and inflammation 330
  - markers of cell proliferation 210–11, 227–8, 275–6
  - oncogenesis 330–1
  - shedding/dissemination 11–12
- ultrasonography, for screening 120–1
- unpublished clinical trials, high-dose chemotherapy 323
- urokinase, marker of lack of response to endocrine therapy 227–8
- vaccines 300, 334
- vaginal atrophy
  - oestrogen topical 76
  - tibolone 76
- vascular events, tamoxifen studies 46
- vasomotor symptoms, short-term HRT 76
- vinorelbine 270
  - advanced disease 297
- vitamin E 75
- vomiting 372–3
- WHO analgesic ladder 358–9
- Women’s Health Initiative, National Institutes of Health 80
- Women’s International Study of Long-Duration Oestrogen Use after Menopause (WISDOM) 80
- X chromosome, androgen receptor gene 64
- zoledronate *see* bisphosphonates